<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00420212</url>
  </required_header>
  <id_info>
    <org_study_id>109MS301</org_study_id>
    <nct_id>NCT00420212</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis</brief_title>
  <acronym>DEFINE</acronym>
  <official_title>A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if treatment with BG00012 can decrease the number of MS relapses during a
      certain time period. To determine if, over time, BG00012 treatment can decrease the number of
      certain types of brain lesions commonly seen in MS patients and slow down the time it takes
      for the disease to get worse.

      The purpose of this study is also to determine the safety of BG00012 and how well it is
      tolerated. Another goal is to see what effect BG00012 may have on tests and evaluations used
      to assess MS.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Subjects Relapsed</measure>
    <time_frame>2 years</time_frame>
    <description>A protocol-defined relapse was defined as new or recurrent neurologic symptoms not associated with fever or infection that lasted at least 24 hours, and were separated by at least 30 days from onset of a preceding relapse. All protocol-defined relapses were evaluated by an independent neurolgic evaluation committee. The proportion of subjects with a relapse was estimated using the Kaplan-Meier method, which was based on the time-to-first-relapse survival distribution.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of New or Newly Enlarging T2 Hyperintense Lesions</measure>
    <time_frame>2 years</time_frame>
    <description>The number of new or newly enlarging T2 hyperintense lesions at 2 years that developed in each subject compared to baseline assessed on brain magnetic resonance imaging (MRI) scans. The estimates of mean T2 lesion count were calculated from a negative binomial regression model adjusted for region and baselineT2 lesion volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Gadolinium-enhancing T1-weighted Lesions</measure>
    <time_frame>2 years</time_frame>
    <description>The number of Gd-enhancing lesions was assessed using brain MRI scans following administration of gadolinium, a contrast agent. The mean number of Gd-enhancing lesions at 2 years was the average of the number of lesions at 2 years in a treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Gadolinium (Gd)-Enhancing Lesions</measure>
    <time_frame>2 years</time_frame>
    <description>Note: This outcome measure represents the categorical analysis for the previously listed secondary outcome measure &quot;Number of Gadolinium-enhancing T1-weighted lesions&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Relapse Rate</measure>
    <time_frame>2 years</time_frame>
    <description>A protocol-defined relapse was defined as new or recurrent neurologic symptoms not associated with fever or infection that lasted at least 24 hours, and were separated by at least 30 days from onset of a preceding relapse. All protocol-defined relapses were evaluated by an independent neurologic evaluation committee. The adjusted annualized relapse rate was calculated from a negative binomial regression model, adjusted for baseline EDSS (≤ 2.0 vs. &gt;2.0), age (&lt;40 versus ≥40 years), region, and the number of relapses in the 1 year prior to enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Experiencing Progression of Disability Assessed Using the Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>2 years</time_frame>
    <description>The EDSS is based on a standardized neurological examination and focuses on symptoms that commonly occur in MS. EDSS scores range from 0.0 (normal) to 10.0 (death due to MS). Disability progression was defined as ≥ 1.0 point increase in subjects with a baseline EDSS of ≥1.0, or a ≥1.5 point increase in subjects with a baseline EDSS = 0, and required that the increase from baseline was confirmed ≥12 weeks later. The proportion of subjects with confirmed (12-week) disability progression was estimated using the Kaplan-Meier method, which was based on the time-to-first-progression survival distribution.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1234</enrollment>
  <condition>Relapsing-Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received two placebo capsules orally three times daily (TID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BG00012 240 mg Twice Daily (BID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BG00012 240 mg 3 Times Daily (TID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received two 120 mg BG00012 capsules orally three times daily (TID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BG00012</intervention_name>
    <arm_group_label>BG00012 240 mg Twice Daily (BID)</arm_group_label>
    <arm_group_label>BG00012 240 mg 3 Times Daily (TID)</arm_group_label>
    <other_name>dimethyl fumarate</other_name>
    <other_name>Tecfidera®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Unless otherwise specified, to be eligible to participate in this study, candidates
             must meet the following eligibility criteria at the time of the randomization:

          -  Must have a confirmed diagnosis of RRMS according to McDonald criteria #1-4.

          -  Must have a baseline EDSS between 0.0 and 5.0, inclusive.

          -  Must have relapsing-remitting disease course.

        Key Exclusion Criteria:

          -  Unless otherwise specified, candidates will be excluded from study entry if any of the
             following exclusion criteria exist at randomization:

          -  Other chronic disease of the immune system, malignancies, acute urologic, pulmonary,
             gastrointestinal disease.

          -  Pregnant or nursing women.

        Note: Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palos Heights</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brighton</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hopedale</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lexington</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chatswood</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fitzroy</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Geelong</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kogarah</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liverpool</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newcastle</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <state>Vienna</state>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Diepenbeek</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lommel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sijsele-Damme</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woluwe</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Banja Luka</city>
        <state>Republic of Srpksa</state>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Burnaby</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Levis</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jihlava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Opava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plzen</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Teplice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bad Neustadt-Saale</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dusseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gieben</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Munchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Munster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osnabruck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Westerstede</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ioannina</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guatemala City</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chenna</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coimbatore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lucknow</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beer Yaakov</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Skopje</city>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Luis Potosi</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kishinev</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sittard</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grafton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kragujevac</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nis</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novi Sad</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Martin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rosebank</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poltava</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaporozhye</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Staffordshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vienna</city>
        <country>Virgin Islands (U.S.)</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bosnia and Herzegovina</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Guatemala</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Macedonia, The Former Yugoslav Republic of</country>
    <country>Mexico</country>
    <country>Moldova, Republic of</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Switzerland</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
    <country>Virgin Islands (U.S.)</country>
  </location_countries>
  <removed_countries>
    <country>Belarus</country>
    <country>Bulgaria</country>
    <country>Kazakhstan</country>
    <country>Russian Federation</country>
    <country>Sweden</country>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2007</study_first_submitted>
  <study_first_submitted_qc>January 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2007</study_first_posted>
  <results_first_submitted>May 5, 2014</results_first_submitted>
  <results_first_submitted_qc>May 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 2, 2014</results_first_posted>
  <disposition_first_submitted>October 31, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>October 31, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 2, 2012</disposition_first_posted>
  <last_update_submitted>January 13, 2015</last_update_submitted>
  <last_update_submitted_qc>January 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relapsing</keyword>
  <keyword>oral</keyword>
  <keyword>remitting</keyword>
  <keyword>multiple sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dimethyl Fumarate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were screened and enrolled at 198 investigational sites in 28 countries.</recruitment_details>
      <pre_assignment_details>From screening, 1237 eligible subjects were equally randomized. Of these, 1234 subjects received at least one dose of study treatment and comprised the intent-to-treat (ITT) and safety populations.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received two placebo capsules orally three times daily (TID)</description>
        </group>
        <group group_id="P2">
          <title>BG00012 240 mg Twice Daily (BID)</title>
          <description>Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)</description>
        </group>
        <group group_id="P3">
          <title>BG00012 240 mg 3 Times Daily (TID)</title>
          <description>Participants received two 120 mg BG00012 capsules orally three times daily (TID)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="408">408 participants were dosed; 410 participants were randomized</participants>
                <participants group_id="P2" count="410">410 participants were dosed; 411 participants were randomized</participants>
                <participants group_id="P3" count="416">416 participants were dosed; 416 participants were randomized</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="317"/>
                <participants group_id="P2" count="315"/>
                <participants group_id="P3" count="320"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="95"/>
                <participants group_id="P3" count="96"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other-Unspecified</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received two placebo capsules orally three times daily (TID)</description>
        </group>
        <group group_id="B2">
          <title>BG00012 240 mg Twice Daily (BID)</title>
          <description>Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)</description>
        </group>
        <group group_id="B3">
          <title>BG00012 240 mg 3 Times Daily (TID)</title>
          <description>Participants received two 120 mg BG00012 capsules orally three times daily (TID)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="408"/>
            <count group_id="B2" value="410"/>
            <count group_id="B3" value="416"/>
            <count group_id="B4" value="1234"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.5" spread="9.14"/>
                    <measurement group_id="B2" value="38.1" spread="9.11"/>
                    <measurement group_id="B3" value="38.8" spread="8.85"/>
                    <measurement group_id="B4" value="38.5" spread="9.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="306"/>
                    <measurement group_id="B2" value="296"/>
                    <measurement group_id="B3" value="306"/>
                    <measurement group_id="B4" value="908"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="110"/>
                    <measurement group_id="B4" value="326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Expanded Disability Status Scale (EDSS) score</title>
          <description>The EDSS scores range from 0.0 (normal exam) to 10.0 (death due to MS).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.48" spread="1.241"/>
                    <measurement group_id="B2" value="2.40" spread="1.290"/>
                    <measurement group_id="B3" value="2.36" spread="1.188"/>
                    <measurement group_id="B4" value="2.42" spread="1.240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean number of relapses within the previous 3 years</title>
          <units>Number of relapses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.5" spread="1.56"/>
                    <measurement group_id="B2" value="2.5" spread="1.44"/>
                    <measurement group_id="B3" value="2.4" spread="1.27"/>
                    <measurement group_id="B4" value="2.5" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean number of relapses within the past 12 months</title>
          <units>Number of relapses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.3" spread="0.67"/>
                    <measurement group_id="B2" value="1.3" spread="0.67"/>
                    <measurement group_id="B3" value="1.3" spread="0.60"/>
                    <measurement group_id="B4" value="1.3" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time since first multiple sclerosis (MS) diagnosis</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.8" spread="5.78"/>
                    <measurement group_id="B2" value="5.6" spread="5.39"/>
                    <measurement group_id="B3" value="5.1" spread="5.29"/>
                    <measurement group_id="B4" value="5.5" spread="5.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean number of gadolinium (Gd) enhancing lesions</title>
          <description>This baseline measure could only be assessed in the magnetic resonance imaging (MRI) cohort. The MRI cohort included 540 intent-to-treat (ITT) subjects who were enrolled at sites that participated in the MRI portion of the study and who had MRI data (180 placebo, 176 BG00012 BID, 184 BG00012 TID). Sites could participate only if their MRI capability was validated by the independent MRI reading center. Approximately 95% of all subjects enrolled at MRI sites participated in the MRI portion of the study.</description>
          <units>Number of Gd enhancing lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.6" spread="3.45"/>
                    <measurement group_id="B2" value="1.2" spread="3.30"/>
                    <measurement group_id="B3" value="1.2" spread="4.10"/>
                    <measurement group_id="B4" value="1.4" spread="3.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Subjects Relapsed</title>
        <description>A protocol-defined relapse was defined as new or recurrent neurologic symptoms not associated with fever or infection that lasted at least 24 hours, and were separated by at least 30 days from onset of a preceding relapse. All protocol-defined relapses were evaluated by an independent neurolgic evaluation committee. The proportion of subjects with a relapse was estimated using the Kaplan-Meier method, which was based on the time-to-first-relapse survival distribution.</description>
        <time_frame>2 years</time_frame>
        <population>The analysis was based on the ITT population, defined as all subjects who were randomized and received at least 1 dose of study medication. Among subjects who switched to an alternative therapy for multiple sclerosis, all the data before the switch were used for the analysis. In all other subjects, all relapses were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received two placebo capsules orally three times daily (TID)</description>
          </group>
          <group group_id="O2">
            <title>BG00012 240 mg Twice Daily (BID)</title>
            <description>Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)</description>
          </group>
          <group group_id="O3">
            <title>BG00012 240 mg 3 Times Daily (TID)</title>
            <description>Participants received two 120 mg BG00012 capsules orally three times daily (TID)</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Relapsed</title>
          <description>A protocol-defined relapse was defined as new or recurrent neurologic symptoms not associated with fever or infection that lasted at least 24 hours, and were separated by at least 30 days from onset of a preceding relapse. All protocol-defined relapses were evaluated by an independent neurolgic evaluation committee. The proportion of subjects with a relapse was estimated using the Kaplan-Meier method, which was based on the time-to-first-relapse survival distribution.</description>
          <population>The analysis was based on the ITT population, defined as all subjects who were randomized and received at least 1 dose of study medication. Among subjects who switched to an alternative therapy for multiple sclerosis, all the data before the switch were used for the analysis. In all other subjects, all relapses were included in the analysis.</population>
          <units>Proportion of subjects,confirmed relapse</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="416"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.461"/>
                    <measurement group_id="O2" value="0.270"/>
                    <measurement group_id="O3" value="0.260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of New or Newly Enlarging T2 Hyperintense Lesions</title>
        <description>The number of new or newly enlarging T2 hyperintense lesions at 2 years that developed in each subject compared to baseline assessed on brain magnetic resonance imaging (MRI) scans. The estimates of mean T2 lesion count were calculated from a negative binomial regression model adjusted for region and baselineT2 lesion volume</description>
        <time_frame>2 years</time_frame>
        <population>Of the 540 subjects included in the MRI cohort, 469 subjects (165 placebo, 152 BG00012 BID, 152 BG00012 TID) had post-baseline T2 data and were included in the analysis. Missing data before the use of alternative MS medications and visits after patients switched to alternative MS medications were imputed with the use of a constant rate assumption.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received two placebo capsules orally three times daily (TID)</description>
          </group>
          <group group_id="O2">
            <title>BG00012 240 mg BID</title>
            <description>Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)</description>
          </group>
          <group group_id="O3">
            <title>BG00012 240 mg TID</title>
            <description>Participants received two 120 mg BG00012 capsules orally three times daily (TID)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of New or Newly Enlarging T2 Hyperintense Lesions</title>
          <description>The number of new or newly enlarging T2 hyperintense lesions at 2 years that developed in each subject compared to baseline assessed on brain magnetic resonance imaging (MRI) scans. The estimates of mean T2 lesion count were calculated from a negative binomial regression model adjusted for region and baselineT2 lesion volume</description>
          <population>Of the 540 subjects included in the MRI cohort, 469 subjects (165 placebo, 152 BG00012 BID, 152 BG00012 TID) had post-baseline T2 data and were included in the analysis. Missing data before the use of alternative MS medications and visits after patients switched to alternative MS medications were imputed with the use of a constant rate assumption.</population>
          <units>Number of lesions</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" lower_limit="12.9" upper_limit="22.4"/>
                    <measurement group_id="O2" value="2.6" lower_limit="2.0" upper_limit="3.5"/>
                    <measurement group_id="O3" value="4.4" lower_limit="3.2" upper_limit="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Gadolinium-enhancing T1-weighted Lesions</title>
        <description>The number of Gd-enhancing lesions was assessed using brain MRI scans following administration of gadolinium, a contrast agent. The mean number of Gd-enhancing lesions at 2 years was the average of the number of lesions at 2 years in a treatment group.</description>
        <time_frame>2 years</time_frame>
        <population>Of the 540 subjects included in the MRI cohort, 469 (165 placebo,152 BG00012 BID,152 BG00012 TID) had post-baseline Gd-enhancing lesion data &amp; were included in the analysis. Missing data before the use of alternative MS medications &amp; visits after patients switched to alternative MS medications were imputed with the use of a constant rate assumption</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received two placebo capsules orally three times daily (TID)</description>
          </group>
          <group group_id="O2">
            <title>BG00012 240 mg BID</title>
            <description>Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)</description>
          </group>
          <group group_id="O3">
            <title>BG00012 240 mg TID</title>
            <description>Participants received two 120 mg BG00012 capsules orally three times daily (TID)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Gadolinium-enhancing T1-weighted Lesions</title>
          <description>The number of Gd-enhancing lesions was assessed using brain MRI scans following administration of gadolinium, a contrast agent. The mean number of Gd-enhancing lesions at 2 years was the average of the number of lesions at 2 years in a treatment group.</description>
          <population>Of the 540 subjects included in the MRI cohort, 469 (165 placebo,152 BG00012 BID,152 BG00012 TID) had post-baseline Gd-enhancing lesion data &amp; were included in the analysis. Missing data before the use of alternative MS medications &amp; visits after patients switched to alternative MS medications were imputed with the use of a constant rate assumption</population>
          <units>Number of lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="4.15"/>
                    <measurement group_id="O2" value="0.1" spread="0.63"/>
                    <measurement group_id="O3" value="0.5" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Gadolinium (Gd)-Enhancing Lesions</title>
        <description>Note: This outcome measure represents the categorical analysis for the previously listed secondary outcome measure &quot;Number of Gadolinium-enhancing T1-weighted lesions&quot;</description>
        <time_frame>2 years</time_frame>
        <population>Of the 540 subjects included in the MRI cohort, 469 (165 placebo,152 BG00012 BID,152 BG00012 TID) had post-baseline Gd-enhancing lesion data &amp; were included in the analysis. Missing data before the use of alternative MS medications &amp; visits after patients switched to alternative MS medications were imputed with the use of a constant rate assumption</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received two placebo capsules orally three times daily (TID)</description>
          </group>
          <group group_id="O2">
            <title>BG00012 240 mg Twice Daily (BID)</title>
            <description>Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)</description>
          </group>
          <group group_id="O3">
            <title>BG00012 240 mg 3 Times Daily (TID)</title>
            <description>Participants received two 120 mg BG00012 capsules orally three times daily (TID)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Gadolinium (Gd)-Enhancing Lesions</title>
          <description>Note: This outcome measure represents the categorical analysis for the previously listed secondary outcome measure &quot;Number of Gadolinium-enhancing T1-weighted lesions&quot;</description>
          <population>Of the 540 subjects included in the MRI cohort, 469 (165 placebo,152 BG00012 BID,152 BG00012 TID) had post-baseline Gd-enhancing lesion data &amp; were included in the analysis. Missing data before the use of alternative MS medications &amp; visits after patients switched to alternative MS medications were imputed with the use of a constant rate assumption</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="142"/>
                    <measurement group_id="O3" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 lesion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-4 lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=5 lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Relapse Rate</title>
        <description>A protocol-defined relapse was defined as new or recurrent neurologic symptoms not associated with fever or infection that lasted at least 24 hours, and were separated by at least 30 days from onset of a preceding relapse. All protocol-defined relapses were evaluated by an independent neurologic evaluation committee. The adjusted annualized relapse rate was calculated from a negative binomial regression model, adjusted for baseline EDSS (≤ 2.0 vs. &gt;2.0), age (&lt;40 versus ≥40 years), region, and the number of relapses in the 1 year prior to enrollment.</description>
        <time_frame>2 years</time_frame>
        <population>The ITT population was defined as all subjects who were randomized and received at least 1 dose of study medication. Among subjects who switched to an alternative therapy for multiple sclerosis, all the data before the switch were used for the analysis. In all other subjects, all relapses were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received two placebo capsules orally three times daily (TID)</description>
          </group>
          <group group_id="O2">
            <title>BG00012 240 mg BID</title>
            <description>Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)</description>
          </group>
          <group group_id="O3">
            <title>BG00012 240 mg TID</title>
            <description>Participants received two 120 mg BG00012 capsules orally three times daily (TID)</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Relapse Rate</title>
          <description>A protocol-defined relapse was defined as new or recurrent neurologic symptoms not associated with fever or infection that lasted at least 24 hours, and were separated by at least 30 days from onset of a preceding relapse. All protocol-defined relapses were evaluated by an independent neurologic evaluation committee. The adjusted annualized relapse rate was calculated from a negative binomial regression model, adjusted for baseline EDSS (≤ 2.0 vs. &gt;2.0), age (&lt;40 versus ≥40 years), region, and the number of relapses in the 1 year prior to enrollment.</description>
          <population>The ITT population was defined as all subjects who were randomized and received at least 1 dose of study medication. Among subjects who switched to an alternative therapy for multiple sclerosis, all the data before the switch were used for the analysis. In all other subjects, all relapses were included in the analysis.</population>
          <units>Relapses per year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="416"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.364" lower_limit="0.303" upper_limit="0.436"/>
                    <measurement group_id="O2" value="0.172" lower_limit="0.138" upper_limit="0.214"/>
                    <measurement group_id="O3" value="0.189" lower_limit="0.153" upper_limit="0.234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Experiencing Progression of Disability Assessed Using the Expanded Disability Status Scale (EDSS)</title>
        <description>The EDSS is based on a standardized neurological examination and focuses on symptoms that commonly occur in MS. EDSS scores range from 0.0 (normal) to 10.0 (death due to MS). Disability progression was defined as ≥ 1.0 point increase in subjects with a baseline EDSS of ≥1.0, or a ≥1.5 point increase in subjects with a baseline EDSS = 0, and required that the increase from baseline was confirmed ≥12 weeks later. The proportion of subjects with confirmed (12-week) disability progression was estimated using the Kaplan-Meier method, which was based on the time-to-first-progression survival distribution.</description>
        <time_frame>2 years</time_frame>
        <population>The analysis population consisted of the ITT population (all subjects who were randomized and received at least 1 dose of study medication) who had a baseline EDSS assessment. Analysis were based on all observed data. Onset of disability progression must begin before a subject switched to alternative MS medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received two placebo capsules orally three times daily (TID)</description>
          </group>
          <group group_id="O2">
            <title>BG00012 240 mg BID</title>
            <description>Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)</description>
          </group>
          <group group_id="O3">
            <title>BG00012 240 mg TID</title>
            <description>Participants received two 120 mg BG00012 capsules orally three times daily (TID)</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Experiencing Progression of Disability Assessed Using the Expanded Disability Status Scale (EDSS)</title>
          <description>The EDSS is based on a standardized neurological examination and focuses on symptoms that commonly occur in MS. EDSS scores range from 0.0 (normal) to 10.0 (death due to MS). Disability progression was defined as ≥ 1.0 point increase in subjects with a baseline EDSS of ≥1.0, or a ≥1.5 point increase in subjects with a baseline EDSS = 0, and required that the increase from baseline was confirmed ≥12 weeks later. The proportion of subjects with confirmed (12-week) disability progression was estimated using the Kaplan-Meier method, which was based on the time-to-first-progression survival distribution.</description>
          <population>The analysis population consisted of the ITT population (all subjects who were randomized and received at least 1 dose of study medication) who had a baseline EDSS assessment. Analysis were based on all observed data. Onset of disability progression must begin before a subject switched to alternative MS medication.</population>
          <units>Proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
                <count group_id="O2" value="409"/>
                <count group_id="O3" value="416"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.271"/>
                    <measurement group_id="O2" value="0.164"/>
                    <measurement group_id="O3" value="0.177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <desc>The safety population consisted of all subjects who received at least 1 dose of study treatment. Safety data were analyzed by actual treatment received. Among subjects who switched to an alternative therapy for MS, all the data before the switch were used for the analysis. In all other subjects, all data were included in the analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received two placebo capsules orally three times daily (TID)</description>
        </group>
        <group group_id="E2">
          <title>BG00012 240 mg Twice Daily (BID)</title>
          <description>Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)</description>
        </group>
        <group group_id="E3">
          <title>BG00012 240 mg 3 Times Daily (TID)</title>
          <description>Participants received two 120 mg BG00012 capsules orally three times daily (TID)</description>
        </group>
        <group group_id="E4">
          <title>Total BG00012</title>
          <description>Combined BG00012 240 mg twice daily (BID) dose group and BG00012 240 mg 3 times daily (TID) dose group</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="139" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Microcytic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo Positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Endocrinopathy Diencephalic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Abdominal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Gastrontestinal Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Hiatus Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Colitis Ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Peritoneal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Pelvic Mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Hepatitis Cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Anaphylactoid Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>H1N1 Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Peritonsillar Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Post Viral Fatigue Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Vulval Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Anal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Diarrhoea Infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Pelvic Inflammatory Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Reiter's Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Tuberculosis Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Meniscus Lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Postoperative Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Procedural Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Radius Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Traumatic Brain Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Wrist Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Femoral Neck Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Tendon Rupture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Tibia Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Allergy Test</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Blood Glucose Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Colonoscopy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Investigation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Medical Observation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Hepatic Enzyme Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Sjogren's Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Synovial Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign Lung Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Cervix Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Neurilemmoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Transitional Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Uterine Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple Sclerosis Relapse</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="71" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Neurological Symptom</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Altered State of Conciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Glossopharyngeal Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Multiple Sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Transient Global Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Transverse Sinus Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Viith Nerve Paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Grand Mal Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Loss of Conciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Restless Legs Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Adjustment Disorder with Depressed Mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Generalized Anxiety Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Narcissistic Personality Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Ureterocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Ovarian Cyst Ruptured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Menstrual Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Pelvic Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Uterine Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Pneumonia Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Stevens-Johnson Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Dermatitis Allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Female Sterilization</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Venous Stent Insertion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Varicose Vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>Peripheral Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="384" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="394" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="393" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="787" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="78" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="140" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="107" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="92" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="83" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="69" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="120" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="109" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="217" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="114" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="109" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="82" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="51" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="56" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>ALBUMIN URINE PRESENT</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="105" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="83" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="66" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>MULTIPLE SCLEROSIS RELAPSE</sub_title>
                <counts group_id="E1" subjects_affected="181" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="107" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="216" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="78" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="159" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="73" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="62" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>PROTEINURIA</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="88" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>MICROALBUMINURIA</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PRURITIS</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="75" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="61" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>FLUSHING</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="153" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="132" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="285" subjects_at_risk="826"/>
              </event>
              <event>
                <sub_title>HOT FLUSH</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="60" subjects_at_risk="826"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The provisions of the agreements are subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Biogen Idec Study Medical Director</name_or_title>
      <organization>Biogen Idec</organization>
      <email>clinicaltrials@biogenidec.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

